Characteristic | |
---|---|
Median age at Re-RT (years) | 53.5 |
Range: age at Re-RT (years) | 21.8 – 81.1 |
< 50 years at Re-RT | 26/64 (40.6%) |
≥ 50 years at Re-RT | 38/64 (59.4%) |
Male | 34/64 (53.1%) |
Female | 30/64 (46.9%) |
WHO IV | 53/64 (82.8%) |
WHO III | 11/64 (17.2%) |
Karnofsky performance score < 70 | 13/64 (20.3%) |
Karnofsky performance score ≥ 70 | 51/64 (79.7%) |
Median time (RT to Re-RT) (months) | 13.4 |
Range: time (RT to Re-RT) (months) | 2.7 – 202.6 |
Time from RT to Re-RT ≤ 12 months | 21/64 (32.8%) |
Time from RT to Re-RT > 12 months | 43/64 (67.2%) |
Concurrent chemotherapy | 36/64 (56.3%) |
Carboplatin/etoposide | 24/64 (37.5%) |
Temozolomide | 12/64 (18.8%) |
Complete resection before Re-RT | 8/64 (12.5%) |
Incomplete/no resection before Re-RT | 56/64 (87.5%) |